# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-280215
Filing Date
2025-11-13
Accepted
2025-11-13 16:17:24
Documents
71
Period of Report
2025-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | acrv-20250930.htm iXBRL | 10-Q | 2081265
2 | EX-31.1 | acrv-ex31_1.htm | EX-31.1 | 17622
3 | EX-31.2 | acrv-ex31_2.htm | EX-31.2 | 17579
4 | EX-32.1 | acrv-ex32_1.htm | EX-32.1 | 11295
5 | EX-32.2 | acrv-ex32_2.htm | EX-32.2 | 11256
| Complete submission text file | 0001193125-25-280215.txt |  | 8292576

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | acrv-20250930.xsd | EX-101.SCH | 1064069
74 | EXTRACTED XBRL INSTANCE DOCUMENT | acrv-20250930_htm.xml | XML | 1505659

Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41551 | Film No.: 251478762
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)